Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.